- Home
- GGR vs ZNTL Comparison
GGR vs ZNTL Comparison
Compare GGR & ZNTL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- GGR
- ZNTL
- Stock Information
- Founded
- GGR 2011
- ZNTL 2014
- Country
- GGR Taiwan
- ZNTL United States
- Employees
- GGR N/A
- ZNTL N/A
- Industry
- GGR Auto Manufacturing
- ZNTL Biotechnology: Pharmaceutical Preparations
- Sector
- GGR Consumer Discretionary
- ZNTL Health Care
- Exchange
- GGR Nasdaq
- ZNTL Nasdaq
- Market Cap
- GGR 114.3M
- ZNTL 102.2M
- IPO Year
- GGR N/A
- ZNTL 2020
- Fundamental
- Price
- GGR $0.25
- ZNTL $1.21
- Analyst Decision
- GGR Hold
- ZNTL Buy
- Analyst Count
- GGR 2
- ZNTL 9
- Target Price
- GGR $0.50
- ZNTL $8.69
- AVG Volume (30 Days)
- GGR 373.8K
- ZNTL 689.9K
- Earning Date
- GGR 05-08-2025
- ZNTL 05-14-2025
- Dividend Yield
- GGR N/A
- ZNTL N/A
- EPS Growth
- GGR N/A
- ZNTL N/A
- EPS
- GGR N/A
- ZNTL N/A
- Revenue
- GGR $304,551,000.00
- ZNTL $26,865,000.00
- Revenue This Year
- GGR N/A
- ZNTL N/A
- Revenue Next Year
- GGR $5.00
- ZNTL N/A
- P/E Ratio
- GGR N/A
- ZNTL N/A
- Revenue Growth
- GGR N/A
- ZNTL N/A
- 52 Week Low
- GGR $0.19
- ZNTL $1.01
- 52 Week High
- GGR $1.76
- ZNTL $13.00
- Technical
- Relative Strength Index (RSI)
- GGR 42.46
- ZNTL 42.23
- Support Level
- GGR $0.24
- ZNTL $1.18
- Resistance Level
- GGR $0.27
- ZNTL $1.27
- Average True Range (ATR)
- GGR 0.02
- ZNTL 0.07
- MACD
- GGR -0.00
- ZNTL 0.01
- Stochastic Oscillator
- GGR 9.09
- ZNTL 30.30
About GGR Gogoro Inc.
Gogoro Inc is focused on eliminating the barriers to electric fuel adoption to bring swappable electric power within reach of every urban rider. Its battery swapping technology compromises an interoperable platform that seamlessly integrates a comprehensive ecosystem of hardware, software, and services, which consists of Gogoro Smart Batteries, GoStations, Gogoro Network Software & Battery Management Systems, Smartscooter, and related components and kits. Geographical presence in Taiwan and Other countries, majority of its revenue comes from Tiwan.
About ZNTL Zentalis Pharmaceuticals Inc.
Zentalis Pharmaceuticals Inc is a clinical-stage biopharmaceutical company developing azenosertib (ZN-c3), a potentially first-in-class and best-in-class WEE1 inhibitor for patients with Cyclin E1-positive platinum-resistant ovarian cancer (Cyclin E1+ PROC). The Company manages its operations as a single segment for the purposes of assessing performance and making operating decisions.